Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291913 · ClinicalTrials.gov registry record · Phase 2
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02291913 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 48 participants.
The verdict
NCT02291913, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Many patients with ER-positive or PR-positive breast cancer are treated with endocrine therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients often experience disease progression. Everolimus, in combination with exemestane, has shown activity in endocrine-resistant disease. This study will evaluate the efficacy of Everolimus+ anti-estrogen therapy in patients with ER-positive metastatic breast cancer who have progressed after receiving anti-estrogen therapy.
Interventions
- DRUG Tamoxifen
- DRUG Anastrozole
- DRUG Exemestane
- DRUG Everolimus
- DRUG Fulvestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-12-18 |
| Est. Completion | 2019-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02291913
The ClinicalTrials.gov registry entry for NCT02291913 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tamoxifen is the first listed.
NCT02291913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02291913 about?
NCT02291913 is a clinical study titled "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer". Many patients with ER-positive or PR-positive breast cancer are treated with endocrine therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients often experience disease progression. Everolimus, in combination with exemestane, has shown activity in endocrine-resist...
What is the current status of trial NCT02291913?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2014-12-18. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT02291913?
The interventions under investigation include: Tamoxifen (DRUG), Anastrozole (DRUG), Exemestane (DRUG), Everolimus (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT02291913?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.